# Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation

> **NCT06560801** · PHASE4 · RECRUITING · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 48 (estimated)

## Conditions studied

- Chronic Kidney Diseases

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab

## Key facts

- **NCT ID:** NCT06560801
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-28
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06560801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06560801, "Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06560801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*